Kardigan co-founder and CEO Tassos Gianakakos discusses the new leads his company has found in battling heart disease on ‘The Claman Countdown.’
Kardigan Inc. CEO Tassos Gianakakos details the biotech’s recent IPO on Nasdaq and its commitment to tackling cardiovascular disease, the leading cause of death in the US. Gianakakos highlights three late-stage drug programs, including one for calcific aortic valve disease. He explains how Kardigan utilizes focused studies and innovative approaches to target underlying disease drivers.
Read the full article here